NCT01004133

Brief Summary

With the completion of the human genome project, investigators can now explore new questions in human biology. Previously human genetics focused on highly penetrant, Mendelian traits; however, now rare and common variants can be discovered that affect "common" diseases that have multi-gene architecture with variable penetrance such as breast cancer, diabetes mellitus, and coronary artery disease. This change took place because investigators now have the tools to illuminate the whole genome at once to discover the genetic variants responsible for different disease phenotypes through statistical differences between populations. Besides disease phenotypes, health can be considered a human phenotype that can be studied. Health is not merely the absence of disease but may be viewed as a dynamic ongoing interplay between the environment and the genome to maintain homeostasis. Individuals often attempt to optimize environmental conditions according to ones genome to maximize their health. All individuals possess potentially beneficial and harmful variants depending on the environment. How this dynamic interplay occurs between the genome and environment requires understanding the boundary conditions of the genetic architecture of health and disease and then modeling the system to simulate the observed data. The aging process also affects health. Aging involves a loss of the normal coping responses to internal and external environmental stressors or signals. Investigators now have the tools to uncover from the bottom up the mechanisms involved in maintaining the ability to overcome environmental conditions that can affect health. Against this genomic breakthrough of whole genome association studies, the demographics in the United States are quickly changing. The older population (age \> 65 years) in 2030 is projected to be twice as large as in 2000 representing nearly 20 percent of the total US population. The first baby boomers turn 65 in 2011 and will challenge all facets of health care in the coming decades. The demographic changes underscore the need to understand the mechanisms that promote health and disease in this cohort. Genomic discoveries will help individuals and may reduce medical costs and benefit society. In summary, the objective of this study is to obtain blood and/or saliva samples in order to help model health and disease phenotypes through population genomics. The blood and/or saliva samples may allow for participants' entire genomes to be sequenced if such comprehensive analysis becomes feasible and economical.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
45mo left

Started Aug 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress84%
Aug 2007Jan 2030

Study Start

First participant enrolled

August 1, 2007

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

October 27, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 29, 2009

Completed
20.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

January 17, 2025

Status Verified

January 1, 2025

Enrollment Period

22.4 years

First QC Date

October 27, 2009

Last Update Submit

January 15, 2025

Conditions

Keywords

Age 80 or olderNo chronic disease

Outcome Measures

Primary Outcomes (1)

  • Biorepository Creation

    Create a biorepository from participants' blood and/or saliva donations we will ultimately be able to define genes for various diseases and understand health

    ten years

Study Arms (1)

Subjects 80 years of age or older without chronic diseases.

Eligibility Criteria

Age80 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

General outpatient and community population.

You may qualify if:

  • Age 80 years or older
  • Eligible for blood draw and/or saliva collection
  • Be reliable, cooperative and willing to comply with all protocol-specified procedures
  • Able to understand and grant informed consent
  • Be healthy or have mild medical conditions that may be associated with the normal aging process, including:
  • Hypertension, well controlled (no more than 3 medications)
  • Osteoporosis, Osteopenia and/or osteoarthritis
  • Benign prostatic hypertrophy
  • Cataracts, Glaucoma, Macular Degeneration
  • Dyslipidemia
  • Hypothyroidism
  • Pre-diabetes/impaired fasting glucose (fasting blood glucose 100-126 mg/dL, if known)

You may not qualify if:

  • \< 80 years old
  • Participants have been previously enrolled in The Scripps Genebank Healthy Elderly Cohort
  • Treatment with any investigational agents or devices within thirty days preceding enrollment in the study.
  • Self-reported history or current diagnosis of significant chronic conditions including:
  • Any Cancer (including polycythemia; excluding basal or squamous cell skin cancer).
  • Coronary Artery Disease/Myocardial Infarction
  • Stroke/TIA
  • Deep Vein Thrombosis/Pulmonary Embolus
  • Chronic Renal Disease/Hemodialysis
  • Significant Auto-immune/Inflammatory conditions such as (Rheumatoid Arthritis, Lupus, Crohn's, etc.
  • Alzheimer's/Parkinson's
  • Diabetes (Hemoglobin A1C \> 6.5 % or fasting glucose \>126 mg/dL or treated with oral diabetic medication or insulin if known)
  • Aortic or Cerebral Aneurysm
  • Currently taking any of the following medications on a regular basis:
  • Oral chemotherapeutic agents (ex.: tamoxifen, doxorubicin, mitoxantrone, bleomycin)
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Scripps Translational Science Institute

La Jolla, California, 92037, United States

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

A single blood specimen or saliva specimen is collected from each subject. If blood is collected, approximately thirty eight milliliters of blood will be dispensed as follows: 3 x 8.5 mls DNA Tubes 1 x 2.5 mls RNA tube 1 x 10 mls EBV tube (EDTA) for immortalized cell lines

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

October 27, 2009

First Posted

October 29, 2009

Study Start

August 1, 2007

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

January 17, 2025

Record last verified: 2025-01

Locations